MiraMSC
AssetAlso called MiraMSC-FS-001
Allogeneic umbilical cord-derived mesenchymal stem cell therapy intended to treat frailty.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Trial NCT07705464 is still running. Trial NCT07705464 updated in its registry on Jul 15, 2026. clinicaltrials.gov
Indications
1Frailty
Phase 1, Not yet recruiting, NCT07705464, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors3
- Aging relevance2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.